Marketed Product

CIMZIA®

Full Prescribing Information /  CIMZIA® Product Site

CIMZIA® (certolizumab pegol) marketed by UCB.S.A, is the second marketed product manufactured under XOMA’s license using XOMA’s bacterial cell expression technology.  CIMZIA® received FDA approval in April 2008 for the treatment of Crohn’s disease.  In May 2009, UCB received FDA approval for CIMZIA® for the treatment of moderate to severe rheumatoid arthritis (RA).  CIMZIA® is also in clinical trials for the treatment of psoriasis.

CIMZIA® is an antibody fragment that blocks Tumor Necrosis Factor (TNF) alpha.  

Crohn’s disease is chronic debilitating autoimmune disease that occurs when the immune system inappropriately attacks the gastrointestinal (GI) tract, causing GI symptoms and complications outside the GI tract.  The disease affects approximately 500,000 Americans.

RA is a systemic debilitating autoimmune disease that occurs when the immune system inappropriately attacks joint tissue, causing painful chronic inflammation and irreversible destruction of cartilage, tendons and bones, that often results in chronic pain, loss of function and disability, and can also lead to cardiovascular and pulmonary complications. The disease affects more than two million Americans.

XOMA receives royalties on CIMZIA® sales.

- - -

The above information should not be used as a source for prescribing information.